FDA to seek public comment on interim rule for wartime waivers of informed consent, Pendergast testifies.
FDA RECEIVING "VERY FEW" REQUESTS FOR EMERGENCY RESEARCH INFORMED CONSENT WAIVERS, FDA Deputy Commissioner Mary Pendergast testified at a May 8 hearing of Rep. Shays' (R-Conn.) Government Reform/Human Resources Subcommittee. "FDA has tracked all INDs and [Investigational Device Exemptions] submitted under this rule...to ensure its adequacy for protecting research subjects and to ensure it is appropriately applied," Pendergast said. "To date, there have been very few submissions under this rule. We have received one IDE application and four IND applications under the emergency research rule."
Learn what's happening at the US FDA. On the go.
More from Archive
- • By
This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
- • By
We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.
More from Pink Sheet
- • By
It is unclear in a revised staff manual guide whether Commissioner's National Priority Voucher program approval “recommendations” from the drug and biologic center directors will be advisory or decisional, experts told the Pink Sheet.
- • By
Revised recommendation is based on most recent data on circulating strains in US, where KP.3 is now dominant. Novavax sticks with plans targeting the JN.1 ‘parent strain.’
- • By
Pink Sheet reporter and editors discuss the US FDA’s changes to the COVID-19 vaccine indication and its revocation of the vaccine emergency use authorizations, as well as new vaccine coverage and reimbursement questions.
